Stifel Maintains Buy on Krystal Biotech, Raises Price Target to $220
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha maintains a Buy rating on Krystal Biotech and raises the price target from $204 to $220.
September 11, 2024 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha has reiterated a Buy rating for Krystal Biotech and increased the price target from $204 to $220, indicating confidence in the company's future performance.
The increase in the price target from $204 to $220 by Stifel suggests a positive outlook for Krystal Biotech, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100